IP10 (CXCL10) (NM_001565) Human Tagged ORF Clone Lentiviral Particle

SKU RC203141L4V

Lenti ORF particles, CXCL10 (mGFP-tagged) - Human chemokine (C-X-C motif) ligand 10 (CXCL10), 200ul, >10^7 TU/mL

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: mGFP
• Target Symbol: IP10
• Synonyms: C7; crg-2; gIP-10; IFI10; INP10; IP-10; mob-1; SCYB10
• Vector: pLenti-C-mGFP-P2A-Puro
• Mammalian Cell Selection: Puromycin
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC203141).
• ACCN: NM_001565
• ORF Size: 294 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
• Shipping: Dry Ice

Reference Data

• RefSeq: NM_001565.1
• RefSeq Size: 1227 bp
• RefSeq ORF: 297 bp
• Locus ID: 3627
• UniProt ID: P02778
• Cytogenetics: 4q21.1
• Domains: IL8
• Protein Families: Druggable Genome, Secreted Protein, Transmembrane
• Protein Pathways: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway
• MW: 10.9 kDa
• Summary: This antimicrobial gene encodes a chemokine of the CXC subfamily and ligand for the receptor CXCR3. Binding of this protein to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression. This gene may also be a key regulator of the 'cytokine storm' immune response to SARS-CoV-2 infection. [provided by RefSeq, Sep 2020]